الفهرس 
HEPATOCELLULAR CARCINOMA (HCC)Only 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
ABSTRACT
Background: Ulcerative colitis is a chronic, relapsing and debilitating condition that have significant impact on quality of life. It is characterised by superficial inflammation limited to the mucosa of the colon.
Aim of the Work: to evaluate the role of human beta-defensin 2 (HBD2) in the diagnosis and monitoring activity of ulcerative colitis.
Patients and Methods: This was a Case Control study that was conducted at Internal Medicine and Hepatology Department at Ain Shams University Hospitals. The study was performed on 30 patients who had ulcerative colitis and a group of 30 healthy subjects as a reference range for HBD2 marker.
Results: The mean age of cases with UC was 29.8 years, while control subjects had a slightly higher mean age of 33.9 years. However, this age difference did not reach statistical significance (p=0.155). Furthermore, the distribution of males and females in the UC group (50% each) and the control group (53.3% male and 46.7% female) did not show a significant difference (p=0.796). No significant differences between the studied groups regarding age, sex, smoking and comorbidities. Mean±SD of ulcerative colitis Duration (years) and Motions number / day was 7.0±4.0 and 6.3±1.4 respectively. Pain, Arthralgia and Bloody diarrhea were the most frequent presentation (100.0%, 60.0% and 60.0% respectively).
Conclusion: Based on these findings, it can be concluded that HBD2 is a valuable marker for the diagnosis and monitoring of UC, showing superior diagnostic performance compared to fecal calprotectin.